3//SEC Filing
MORGENTHALER PARTNERS VII LP 3
Accession 0001181431-05-007011
CIK 0001183765other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 7:19 PM ET
Size
10.4 KB
Accession
0001181431-05-007011
Insider Transaction Report
Form 3
MORGENTHALER PARTNERS VII LP
10% Owner
Holdings
- (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (3,312,007 underlying)
Christoffersen Ralph E
Director10% Owner
Holdings
- (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (3,312,007 underlying)
Footnotes (5)
- [F1]Immediately.
- [F2]Not Applicable.
- [F3]Reflects a 1 for 1.6469 reverse stock split effective as of January 26, 2005.
- [F4]Each share is convertible without consideration into 0.6072 shares of Common Stock, after giving effect to a 1 for 1.6469 reverse stock split effective as of January 26, 2005.
- [F5]The shares are held by Morgenthaler Partners VII, LP (MP VII). Ralph E. Christoffersen, a director of Threshold Therapeutics, Inc., is a Partner of Morgenthaler Management Partners VII, LLC (MMP VII), the managing partner of MP VII. Dr. Christoffersen shares voting power over the shares with the other members of MMP VII. The natural persons who have voting or investment power over the shares held of record by MP VII are Robert C. Bellas, Jr., Greg E. Blonder, James W. Broderick, Ralph E. Christoffersen, Andrew S. Lanza, Theodore A. Laufik, Paul H. Levine, Gary R. Little, John D. Lutsi, Gary J. Morgenthaler, Robert D. Pavey, G. Gary Shaffer, Peter G. Taft. Dr. Christoffersen disclaims beneficial ownership of the shares held by MP VII except to the extent of his pecuniary interest therein.
Issuer
THRESHOLD PHARMACEUTICALS INC
CIK 0001183765
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001162183
Filing Metadata
- Form type
- 3
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 7:19 PM ET
- Size
- 10.4 KB